Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Weighted Average) (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Shares Outstanding (Weighted Average) data on file, last reported at $132.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2.48% year-over-year to $132.9 million; the trailing twelve-month figure through Mar 2026 stood at $132.9 million (up 2.48% YoY), and the FY2025 full-year result was $131.0 million, up 2.63% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $132.9 million, up from $131.0 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $132.9 million in Q1 2026 and bottomed at $120.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $126.1 million (2024), against an average of $126.2 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) increased 1.63%; it then climbed 3.37% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $121.7 million in 2022, then advanced by 2.64% to $124.9 million in 2023, then climbed by 2.2% to $127.7 million in 2024, then advanced by 2.63% to $131.0 million in 2025, then grew by 1.44% to $132.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $132.9 million (Q1 2026), $131.0 million (Q4 2025), and $131.4 million (Q3 2025), per Business Quant data.

Peer Comparison